SK267092A3 - (r)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4- -trifluorobutylcarbamoyl)indol-3-ylmethyl]-n-(2- -methylphenylsulphonyl)benzamide in crystalline form, preparation method thereof and pharmaceutical composition containing the same - Google Patents

(r)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4- -trifluorobutylcarbamoyl)indol-3-ylmethyl]-n-(2- -methylphenylsulphonyl)benzamide in crystalline form, preparation method thereof and pharmaceutical composition containing the same Download PDF

Info

Publication number
SK267092A3
SK267092A3 SK2670-92A SK267092A SK267092A3 SK 267092 A3 SK267092 A3 SK 267092A3 SK 267092 A SK267092 A SK 267092A SK 267092 A3 SK267092 A3 SK 267092A3
Authority
SK
Slovakia
Prior art keywords
methyl
ylmethyl
methoxy
trifluorobutylcarbamoyl
benzamide
Prior art date
Application number
SK2670-92A
Other languages
English (en)
Slovak (sk)
Other versions
SK279657B6 (sk
Inventor
Murray W Cuthbert
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of SK279657B6 publication Critical patent/SK279657B6/sk
Publication of SK267092A3 publication Critical patent/SK267092A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK2670-92A 1991-09-05 1992-08-28 (r)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4- -trifluorobutylcarbamoyl)indol-3-ylmethyl]-n-(2- -methylphenylsulphonyl)benzamide in crystalline form, preparation method thereof and pharmaceutical composition containing the same SK267092A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919119001A GB9119001D0 (en) 1991-09-05 1991-09-05 Pharmaceutical agents

Publications (2)

Publication Number Publication Date
SK279657B6 SK279657B6 (sk) 1999-02-11
SK267092A3 true SK267092A3 (en) 1999-02-11

Family

ID=10700953

Family Applications (1)

Application Number Title Priority Date Filing Date
SK2670-92A SK267092A3 (en) 1991-09-05 1992-08-28 (r)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4- -trifluorobutylcarbamoyl)indol-3-ylmethyl]-n-(2- -methylphenylsulphonyl)benzamide in crystalline form, preparation method thereof and pharmaceutical composition containing the same

Country Status (21)

Country Link
US (2) US5352694A (ja)
EP (1) EP0531078B1 (ja)
JP (1) JP2914414B2 (ja)
KR (1) KR100254710B1 (ja)
AT (1) ATE138910T1 (ja)
AU (1) AU646587B2 (ja)
CA (1) CA2076722A1 (ja)
CZ (1) CZ281999B6 (ja)
DE (1) DE69211258T2 (ja)
DK (1) DK0531078T3 (ja)
FI (1) FI102372B (ja)
GB (2) GB9119001D0 (ja)
HK (1) HK18297A (ja)
HU (2) HU213410B (ja)
IL (1) IL102856A (ja)
NO (1) NO178370C (ja)
NZ (1) NZ244016A (ja)
RU (1) RU2095348C1 (ja)
SK (1) SK267092A3 (ja)
TW (1) TW302359B (ja)
ZA (1) ZA926374B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958780A (en) * 1997-06-30 1999-09-28 Boston Advanced Technologies, Inc. Method for marking and identifying liquids
US6149914A (en) * 1999-07-12 2000-11-21 Patel; Jitendra Rambhai Asthma treatment
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
EP1765333A4 (en) 2004-07-14 2008-06-18 Inflammation Res Ct Company Lt PROCESS FOR INHIBITING TUMOR METASTASES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524152A (en) * 1982-12-30 1985-06-18 Pennwalt Corporation 1-Cyano-3-(fluoroalkyl)guanidines for lowering blood pressure
GB8623429D0 (en) * 1985-10-17 1986-11-05 Ici America Inc Carboximide derivatives
MY103259A (en) * 1987-04-15 1993-05-29 Ici America Inc Aliphatic carboxamides
GB8906032D0 (en) * 1988-04-14 1989-04-26 Ici America Inc Hetera-aliphatic carboxamides
GB8927981D0 (en) * 1989-12-11 1990-02-14 Ici Plc Carbamoyl derivative
GB9026427D0 (en) * 1990-12-05 1991-01-23 Ici Plc Chemical process
GB9026425D0 (en) * 1990-12-05 1991-01-23 Ici Plc Process
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)

Also Published As

Publication number Publication date
FI102372B1 (fi) 1998-11-30
HU213410B (en) 1997-06-30
CZ281999B6 (cs) 1997-04-16
NZ244016A (en) 1995-01-27
NO923467D0 (no) 1992-09-04
NO178370B (no) 1995-12-04
KR930005976A (ko) 1993-04-20
HK18297A (en) 1997-02-13
ATE138910T1 (de) 1996-06-15
JPH05194385A (ja) 1993-08-03
KR100254710B1 (ko) 2000-05-01
AU2101292A (en) 1993-03-11
GB9216774D0 (en) 1992-09-23
ZA926374B (en) 1993-03-05
HUT69696A (en) 1995-09-28
HU9202660D0 (en) 1992-10-28
DE69211258D1 (de) 1996-07-11
IL102856A (en) 1996-12-05
RU2095348C1 (ru) 1997-11-10
DE69211258T2 (de) 1996-10-02
SK279657B6 (sk) 1999-02-11
NO178370C (no) 1996-03-13
NO923467L (no) 1993-03-08
FI923869A (fi) 1993-03-06
GB9119001D0 (en) 1991-10-23
HU210879A9 (en) 1995-09-28
US5466826A (en) 1995-11-14
US5352694A (en) 1994-10-04
JP2914414B2 (ja) 1999-06-28
IL102856A0 (en) 1993-01-31
EP0531078A1 (en) 1993-03-10
TW302359B (ja) 1997-04-11
AU646587B2 (en) 1994-02-24
FI102372B (fi) 1998-11-30
CA2076722A1 (en) 1993-03-06
DK0531078T3 (da) 1996-10-14
EP0531078B1 (en) 1996-06-05
FI923869A0 (fi) 1992-08-28
CZ267092A3 (en) 1993-03-17

Similar Documents

Publication Publication Date Title
US20080085903A1 (en) Novel crystalline forms of aripiprazole
EP1202969A2 (de) Biphenylderivate, ihre herstellung und ihre verwendung als mtp-inhibitor
TWI518072B (zh) 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式
BG61323B2 (bg) Производни на пиперидина,тяхното получаване и използването им като лекарства
JP2005508383A (ja) リモナバントの結晶多形、製造方法とそれを含む医薬組成物
US5354760A (en) Crystalline Tiagabine monohydrate, its preparation and use
SK267092A3 (en) (r)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4- -trifluorobutylcarbamoyl)indol-3-ylmethyl]-n-(2- -methylphenylsulphonyl)benzamide in crystalline form, preparation method thereof and pharmaceutical composition containing the same
MXPA03011728A (es) Formas cristalinas novedosas del acido 4-[4-[4- (hidroxidifenilmetil) -1-piperidinil] -1-hidroxibutil] -alfa, alfa -dimetilbencen acetico y su clorohidrato.
CA2031897C (en) Carbamoyl derivatives
WO2015037010A1 (en) Preparation of vilazodone hydrochloride crystalline form iv
US20070032506A1 (en) Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
EP2657232A2 (en) Process for the purification of a benzenesulphonamide compound
US20040058901A1 (en) Crystalline ethanolate solvate form of zafirluskast process for manufacture and pharmaceutical compositions thereof
US20040038985A1 (en) Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride
US20040097528A1 (en) Crystalline solid famciclovir forms I, II, III and preparation thereof
WO2022060945A1 (en) Solid state forms of gefapixant and process for preparation thereof